{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:37:14Z","timestamp":1787503034495,"version":"build-2736575974"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response using tyrosine kinase inhibitors (TKIs) can safely attempt to stop their use. As these medications are very costly, this change in treatment protocols may result in large savings.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate future savings from attempting to stop TKI use among patients with CML who have deep molecular response.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A microsimulation model was developed for this decision analytical modeling study to estimate costs for US adults moving from using a TKI, to attempting discontinuation and then reinitiating TKI therapy, if clinically appropriate. Estimates were calculated for US patients who currently have CML and simulated newly diagnosed cohorts of patients over the next 30 years.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Attempting to stop using a TKI.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Estimated savings after attempted discontinuation of TKI use.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A simulated population of individuals with CML in 2018 and future populations were created using estimates from the SEER*Explorer website. The median age at diagnosis was 66 years for men and 65 years for women. Between 2022 and 2052, the savings associated with eligible patients attempting discontinuation of TKI therapy was estimated at more than $30 billion among those currently diagnosed and over $15 billion among those who will develop CML in the future, for a total savings of over $54 billion by 2052 for drug treatment and polymerase chain reaction testing. The estimate is conservative as it does not account for complications and other health care\u2013associated costs for patients continuing TKI therapy.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this decision analytical modeling study of patients with CML suggest that attempting discontinuation of TKI therapy could save over $54 billion during the next 30 years. Further education for patients and physicians is needed to safely increase the number of patients who can successfully attain treatment-free remission.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.47950","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T11:01:08Z","timestamp":1702897268000},"page":"e2347950","source":"Crossref","is-referenced-by-count":10,"title":["Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia"],"prefix":"10.1001","volume":"6","author":[{"given":"Aaron N.","family":"Winn","sequence":"first","affiliation":[{"name":"Department of Health Systems, Outcomes and Policy, School of Pharmacy, University of Illinois at Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University Medical Center, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W. N.","family":"Deininger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University Medical Center, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Moore","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Oehler","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California at San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Flynn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"24","key":"zoi231401r1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi231401r2","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"The price of drugs for chronic myeloid leukemia (CML) reflects the unsustainable prices of cancer drugs from the perspective of a large group of CML experts.","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"issue":"5","key":"zoi231401r3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi231401r4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"11","key":"zoi231401r5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi231401r6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial.","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"zoi231401r9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic myeloid leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology.","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"zoi231401r10","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"zoi231401r11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"zoi231401r12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"zoi231401r13","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1038\/oby.2007.339","article-title":"Forecasting the obesity epidemic in the aging US population.","volume":"15","author":"Wang","year":"2007","journal-title":"Obesity (Silver Spring)"},{"issue":"23","key":"zoi231401r14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMsa0900459","article-title":"Forecasting the effects of obesity and smoking on US life expectancy.","volume":"361","author":"Stewart","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi231401r15","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1377\/hlthaff.2013.0449","article-title":"More Americans living longer with cardiovascular disease will increase costs while lowering quality of life.","volume":"32","author":"Pandya","year":"2013","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi231401r16","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JOP.19.00301","article-title":"Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib.","volume":"16","author":"Cole","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"zoi231401r17","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"zoi231401r18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jval.2020.05.019","article-title":"Cost-effectiveness of first-line tyrosine kinase inhibitor therapy initiation strategies for chronic myeloid leukemia.","volume":"23","author":"Nguyen","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"zoi231401r20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41375-019-0699-y","article-title":"Do persons with chronic myeloid leukaemia have normal or near normal survival?","volume":"34","author":"Radivoyevitch","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"zoi231401r21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnci\/djab184","article-title":"Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.","volume":"114","author":"Schoenbeck","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"zoi231401r22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.leukres.2019.03.007","article-title":"Patients\u2019 perspectives on the definition of cure in chronic myeloid leukemia.","volume":"80","author":"Flynn","year":"2019","journal-title":"Leuk Res"},{"key":"zoi231401r24","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1182\/blood-2019-125736","article-title":"Tyrosine kinase inhibitor therapy discontinuation in clinical practice in chronic myeloid leukemia\u2014a US physician survey conducted after guideline updates.","volume":"134","author":"Atallah","year":"2019","journal-title":"Blood"},{"key":"zoi231401r7","unstructured":"National Cancer Institute. SEER*Explorer. Updated June 8, 2023. Accessed October 1, 2022. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html"},{"key":"zoi231401r8","unstructured":"Social Security Administration. Actuarial life table. 2020. Accessed October 1, 2022. https:\/\/ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"zoi231401r19","unstructured":"Centers for Medicare & Medicaid Services. Medicare coverage database. 2022. Accessed October 1, 2022. https:\/\/www.cms.gov\/medicare-coverage-database\/search.aspx"},{"key":"zoi231401r23","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014chronic myeloid leukemia (CML). 2022. Accessed October 2, 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2812895\/winn_2023_oi_231401_1701969060.44399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T11:01:13Z","timestamp":1702897273000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2812895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.47950","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}